New Imcivree Indication; Top Pediatric Endo Hospitals; Contrast Dye & Tots' Thyroids

(MedPage Today) -- The FDA approved a new indication for setmelanotide (Imcivree), a melanocortin-4 receptor (MC4R) agonist, for patients with Bardet-Biedl syndrome but rejected a new indication for Alström syndrome, Rhythm Pharmaceuticals...
Source: MedPage Today Endocrinology - Category: Endocrinology Source Type: news